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030 The Journal of Thoracic and Cardbjective: We sought to determine the midterm results of endovascular repair of
therosclerotic aneurysms of the thoracic descending aorta by using second-generation,
ommercially available stent grafts.
ethods: Between 1996 and 2005, 45 patients (mean age, 68  11 years) with
neurysms of the descending thoracic aorta underwent endovascular repair. Aortic
issections, penetrating ulcers, and traumatisms were excluded. The mean follow-up
as 24.7  21.6 months (maximum, 6.7 years).
esults: No patients died, and no conversion to surgical intervention was required
uring the procedures. Three (6.7%) patients died during the first month, and 6
14.7%) died later on. The main complications were strokes (13.3%), vascular
ccess complications (8.9%), aortic complications (6.6%), paraplegia (4.4%), and
udden deaths (4.4%). Nineteen (42%) primary endoleaks were encountered: 3
equired reinterventions, 15 spontaneously thrombosed, and 1 patient died. Except
or 2 sudden unexplained deaths, no aortic complications were observed after 1 month.
ctuarial survival estimates at 1, 3, and 5 years were 87.6%  5.3%, 76.9%  7.4%,
nd 70.6% 9.2%, respectively. Actuarial freedom from death related to the treated
ortic disease was 94.3%  4.0%, 94.3%  4.0%, and 86.4%  8.4% at 1, 3, and
years, respectively. Aspirin status of greater than 3 (P  .005), high aortic
iameter (P  .007), and long covered lengths (P  .02) were determinant for
ortality. Actuarial freedom from complication was 62.6%  7.7%, 58.9% 
.1%, and 58.9%  8.1% at 1, 3, and 5 years, respectively. The location of the
neurysm (P  .05) and a high aortic diameter (P  .04) were both determinants
or endoleaks.
onclusions: Stent grafting of atherosclerotic aneurysm of the thoracic descending
orta is safe and effective. Further studies are mandatory to determine the most
elevant indications and the long-term efficacy of such treatment.
he second half of the 20th century produced significant advances in the
management of patients with aneurysms of the descending thoracic aorta,
and traditional treatment consisted of open surgical graft replacement.
any open surgical techniques were described, but all are associated with
ignificant morbidity and mortality rates, especially in elderly patients with
evere comorbidities.1
The first stent-grafting procedure in the human thoracic aorta was allotted to
olodos and colleagues in 1991.2 It quickly offered the promise of a new 
ess-invasive method of achieving aneurysm exclusion.3 A restricted number o
roups demonstrated technical feasibility with perioperative morbidity and
ortality rates lower than those encountered after conventional surgical treat-
ent.4-12 Even so, the endovascular repair of aneurysms of the descending
iovascular Surgery ● November 2006
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A
CDhoracic aorta is less widespread than procedures carried
ut on the infrarenal aorta. The long-term results are thus
ot well known.
The objective of this study is to report the midterm
esults of endovascular repair of aneurysms of the descending
horacic aorta with the exclusive use of second-generation stent
rafts.
atients and Methods
atients
rom February 1996 through September 2005, 45 consecutive
atients with an average age of 68 11 years (range, 47-81 years)
ere included in a monocentric, nonrandomized, prospective study
pproved by our hospital ethics committee. Informed consent was
btained from all patients or patient families. All patients pre-
ented with an atherosclerotic aneurysm of the descending thoracic
orta. Chronic or acute aortic dissections, penetrating ulcers, and
raumatic ruptures were excluded. The preoperative clinical char-
cteristics are summarized in Table 1. Stent grafting was 
ormed in all cases.
reoperative Imaging
ll patients underwent spiral computed tomographic angiography
canning with 3-dimensional reconstruction before stent graft
lacement so as to determine the location, length, and diameter of
he aneurysm and landing zones, as well as to evaluate the suit-
bility of the iliac and femoral arteries for vascular access. The
reoperative characteristics of the aortic lesions are summarized in
ABLE 1. Preoperative clinical characteristics of the 45 pa-
ients with descending thoracic aortic aneurysms treated
ith endovascular stent grafts
haracteristics
No. of
patients %
perative status
Aspirin 1 2 4.4
Aspirin 2 14 31.1
Aspirin 3 13 28.9
Aspirin 4 16 35.5
Emergent 8 17.8
Non emergent 37 82.2
ther medical problems
Coronary artery disease 24 53.3
Congestive heart failure 19 42.2
Renal insufficiency 10 22.2
Hypertension 34 75.6
Diabetes mellitus 12 26.7
Dyslipidemia 9 20
Stroke 4 8.9
Cigarette smoking 27 60
Chronic pulmonary disease 26 57.8
revious cardiac, thoracic, or vascular surgery 11 24.4able 2. f
The Journal of Thoracicntravascular Device Details, Stent Graft Placement,
nd Postoperative Care
ll intravascular devices used were covered stent grafts: 17 Ex-
luder devices (W. L. Gore & Associates, Elkton, Md), 27 Talent
evices (Medtronic, Inc, Minneapolis, Minn), and 1 Baxter device.
tent graft dimensions were oversized by 10% to 15% compared
ith the landing zone diameters and were at least 30 to 40 mm
onger than the aortic lesion to be treated. All the patients received
n intravenous bolus of heparin at the dose of 75 UI/kg. The
atients were extubated immediately after the procedure and then
upervised in the intensive care unit during the first 24 hours.
nticoagulation was maintained for 48 hours (preventive doses of
ow-weight heparin or calcic heparin according to the blood cre-
tinin level) and then followed by aspirin (250 mg/d).
ollow-up
ollow up consisted of standard chest roentgenography, trans-
sophageal echocardiography, and injected spiral scanner or mag-
etic resonance before discharge and on the 3rd, 6th, 12th, and
8th months. Standard chest roentgenography and injected spiral
canner or magnetic resonance were performed every subsequent
ear. One patient was lost from follow-up (2.2%). Mean follow-up
as 24.7  21.6 months (range, 6 months-6.7 years).
efinitions
he definitions used in this study are described in the literat13
rimary technical success was defined as a complete exclusion of
he aneurysm without an additional procedure and without periop-
rative death or complication. Secondary technical success was
efined as a complete exclusion of the aneurysm after an additional
ndovascular procedure or after spontaneous thrombosis of pri-
ary endoleak within the first month. Endoleak was defined as the
ngiographic, tomodensitometric, or echocardiographic descrip-
ion of blood flow apart from the stent graft. Endoleaks were then
lassified according to the literature.14,15 Any perioperative deaths
ny primary or secondary endoleaks, any failures of the endovas-
ular device, any reinterventions, any deaths related to an aortic
upture, or any sudden unexplained late deaths were considered as
ABLE 2. Preoperative characteristics of the aortic aneu-
ysms
ize of aneurysms
Mean  SD
(mm)
Range
(mm)
neurysm length 70 32.1 30-130
neurysm diameter 67 18 40-100
roximal neck diameter 31 4.5 24-39
istal neck diameter 31.5 3.9 24-40
istance from the left subclavian artery 39.2 27.7 0-130
Location No. of patients %
TAA 1 11 46.6
TAA 2 6 13.3
TAA 3 14 31.1
TAA 4 1 2.2
D, Standard deviation; TAA, thoracic aortic aneurysm.ailures of the treatment.
and Cardiovascular Surgery ● Volume 132, Number 5 1031
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A
CDtatistical Analysis
ll the statistical studies were carried out with the STATA pro-
ram (Stata Corp, College Station, Tex). The continuous variables
ere expressed as means  standard deviations.
The evaluation of actuarial survivals was carried out according
o the Kaplan-Meier nonparametric method. The actuarial rates of
urvival were reported as 1  standard deviation.
The multivariate study was performed by using the log-rank
est, and the factors analyzed as potential predictors of adverse
vents were the age and sex of the patient, aspirin status, comor-
idities (hypertension, diabetes mellitus, previous cerebrovascular
ccident, coronary disease, renal failure, and chronic pulmonary
bstructive disease), emergency operation, location of the aneu-
ysm, locations of the proximal and distal landing zones and their
iameters, maximal diameter of the aneurysm, number of stent
rafts used, covered length, and coverage of the T9-L1 intercostal
rteries.
esults
eriprocedural Outcome
riefly, all accesses were at the level of the underinguinal,
liofemoral junction. An average of 1.2  0.5 stent grafts
ere used (from 1-3). The ostium of the left subclavian
rtery had to be covered in 6 (13.3%) patients. The T9-T11
ortion of the distal part of the descending thoracic aorta
as covered in 16 cases (35.5% of the patients). No deaths
ccurred, and no conversion to open surgical intervention
as required during the procedures. One rupture of the
xternal iliac artery was encountered and required an
liofemoral bypass, which was performed in the same op-
rative period.
arly Outcome
Mortality. Three patients died during the 30 days after
he procedure. The causes of the deaths were 2 pneumoniae
days 6 and 28) and 1 aortoesophageal fistula, which was a
onsequence of the aneurysm before stent grafting (day 30).
he perioperative death rate was 6.7%. The death rate
elated to the treated aortic disease was 2.2%. The death rate
t 30 days of the patients treated in emergency situations
as 12.5%. It was 5.4% for the patients electively treated
P  .05).
Morbidity. In the first 30 days after the intervention, 20
omplications were encountered in 15 patients. Five pa-
ients presented with vascular complications: 2 with isch-
mia of the left upper limb, 2 with pseudoaneurysms of the
eft brachial artery, and 1 with rupture of the iliac artery.
ine patients presented with neurological complications.
erebrovascular accidents were encountered in 6 patients,
nd this was the main complication (13.3%). Of the 6
atients with their left subclavian artery covered, one patient
resented with an ischemic left frontoparietal cerebrovas-
ular accident. In all the other cases, the encephalic injuries
ere diffusely positioned intracerebrally and were also con-istent with the manipulation of intravascular devices in an a
032 The Journal of Thoracic and Cardiovascular Surgery ● Novtherosclerotic aortic arch. Two (4.4%) patients presented
ith paraplegia, and one of them had delayed paraplegia
aused by a rupture of an external iliac artery with collapse.
ne patient presented with a transient left recurrent laryn-
eal nerve paralysis, which was identified during postoper-
tive fiberoptic laryngeal examination. Two patients pre-
ented with severe respiratory complications and died from
neumonia.
Endoleaks, aortic complications, and reinterventions. Nine-
een (42.2%) primary endoleaks were encountered: thirteen
28.8%) type I endoleaks, 1 (2.2%) type II endoleak, and 5
11.1%) type III endoleaks. The primary technical success
ate was 58.8%. Two secondary endoleaks (1 type I and 1
ype III) were observed, both within the first 30 days (4.4%).
Aortic complications occurred in 4 patients. These com-
lications were always associated with primary or second-
ry endoleaks. One contained rupture was associated with a
econdary type III endoleak (day 23; Figure 1, A and B).
hree fistulae were associated with type I endoleak. One
atient died on postoperative day 30 with a de novo aorto-
ronchial fistula (primary type I endoleak). One aortoe-
ophageal fistula (primary type I endoleak) and 1 aortobron-
hial fistula (secondary type I endoleak), which were both
onsequences of the aneurysm before stent grafting, re-
urred on postoperative days 9 and 31, respectively, and
equired reintervention.
Four patients underwent endovascular reintervention
uring the first month (2 primary type I [days 9 and 29], 1
rimary type III [day 21], and 1 secondary type III [day 23]
ndoleaks). Three patients underwent endovascular rein-
ervention because of the persistence of type I primary
ndoleaks in 2 cases (days 37 and 47) and because of a
econdary type I endoleak in 1 case (day 31). The other
rimary endoleaks spontaneously thrombosed after 1
onth. The secondary success rate was 97.8%.
Shrinkage of the aneurysmal sac. During the first
onth, the aneurysmal diameter increased in 3 cases. In 2
ases the increase in diameter was transitory (5 and 10 mm)
ithout detectable endoleak, and in 1 case an increase in
iameter of 30 mm was observed. This latter case was
ssociated with a primary type I endoleak in a patient with
major postoperative complications (cerebrovascular acci-
ent and renal insufficiency), thus preventing the perfor-
ance of reintervention. The patient died on postoperative
ay 30, with no reintervention having been performed. In all
he other cases, the aneurysms shrank. The mean shrinkage
f the aneurysmal sac was 12.8 10.3 mm at the end of the
rst month.
idterm Outcome
o device failure, no migration, no kink or twist, and no
econdary endoleak were observed beyond the 30th day
fter the procedure. No aortic reintervention was required
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A
CDfter the second month. Six patients died beyond the 30th
ay after the procedure. The causes of the deaths were
enal insufficiency 62 days after the procedure, digestive
emorrhage in a cirrhotic patient 1.1 years after the
rocedure, myocardial infarction 1.8 years after the pro-
edure, and cerebrovascular accident 3.1 years after the
rocedure. Two patients died suddenly 1 and 1.6 years
fter the procedure without any obvious cause having
een highlighted and without any autopsy having been
erformed.The Journal of Thoracicurvival Analysis
ctuarial survival estimates 1, 3, and 5 years after the proce-
ure were 87.6%  5.3%, 76.9%  7.4%, and 70.6% 
.2%, respectively (Figure 2, A). More specifically, actua
al freedom from death related to the treated aortic disease
as 94.3%  4.0%, 94.3%  4.0%, and 86.4%  8.4% at
, 3, and 5 years, respectively (Figure 2, B). Actuarial
reedom from complication was 62.6%  7.7%, 58.9% 
.1%, and 58.9%  8.1% at 1, 3, and 5 years, respectively
Figure 2, C).
Figure 1. A and B, Spiral computed
tomogram showing a rupture of the
distal part of the descending thoracic
aorta caused by a secondary type III
endoleak 23 days after the procedure.
Figure 2. A, Overall actuarial survival
estimates. B, Actuarial freedom from
aortic-related death (see text for defi-
nition). C, Actuarial freedom from com-
plication. D, Actuarial freedom from
aortic reintervention.and Cardiovascular Surgery ● Volume 132, Number 5 1033
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1
A
CDActuarial freedom from treatment failure was 90.9% 
.1%, 84.8%  8.2%, and 84.8%  8.2% at 1, 3, and 5
ears, respectively. Actuarial freedom from reintervention
t 1, 3, and 5 years was 71.8%  6.9%. Actuarial freedom
rom aortic reintervention at 1, 3, and 5 years was 77.9% 
.5% (Figure 2, D). All the aortic reinterventions we
erformed during the first year.
ultivariate Analysis
e identified aspirin score equal to or greater than 3 (P
.005), high diameter of the aneurysms (P  .007),
ore than 1 stent graft deployed (P  .0001), and long
overed lengths (P  .02) to portend a significantly
igher likelihood of late death.
We identified the location of the aneurysm (P .05) and
high diameter of the aneurysm (P  .04) to portend a
ignificantly higher likelihood of secondary endoleak.
e identified the location of the aneurysm (P  .01) and
igh diameter of the aneurysm (P  .04) to portend a
ignificantly higher likelihood of treatment failure (P 
01).
iscussion
ven in large-volume centers, morbidity from elective open
urgical repair is significant, with paraplegia and 30-day
ortality rates, respectively, ranging from 3% to 15% and
% to 12%.16,17 Endovascular therapies are considered 
volutionary step toward less-invasive treatments for tho-
acic aortic diseases. The morbidity and mortality associ-
ted with the endovascular repair of thoracic aortic aneu-
ysms seem to be less than those of conventional operative
reatment, despite the fact that many patients were referred
o endovascular treatment because of their high surgical
isks.12 However, in spite of recent advances, endovascu
epair of aneurysms of the descending thoracic aorta re-
ains challenging. Moreover, very little is known about the
ong-term results of such procedures. Except for the series
rom Stanford dealing with the use of first-generation stent
rafts in 103 patients, no more than 4 other series with an
verage follow-up exceeding 2 years are reported in the
iterature.12,18,19 Most of the publications are a mix
ifferent indications, making comparisons difficult. For
hese reasons, only atherosclerotic aneurysms of the de-
cending thoracic aorta were considered for this study, the
oal of which was to determine the midterm results of
ndovascular repair in this indication by using second-
eneration, commercially produced thoracic stent grafts.
Although Dake and coworkers,20 using homemade de-
ices, reported 58% femoral access and up to 30% aortic
pproach, we were able to introduce the stent graft through
n infrainguinal iliofemoral approach in all the cases. Nev-
rtheless, rupture of the external iliac artery was encoun-
ered in 2 patients. In one case this rupture was associated
ith secondary paraplegia because of a hemodynamic col- p
034 The Journal of Thoracic and Cardiovascular Surgery ● Novapse, thus underlining that these vascular complications
ight have severe consequences.
Accurate placement of the stent graft in the arch is one of
he most challenging technical feats, and perioperative stent
raft migration is reported to occur in 2% to 20% of
ases.21,22 We avoided this problem with lower blood p-
ure during deployment, and we did not convert any endo-
ascular procedure to open surgical intervention, which is a
ajor improvement compared with the 4% and 12% con-
ersion rate, respectively, reported by Dake23 and Green-
erg and associates.7 This can also probably be explained 
he technical improvements of the devices used, allowing
artial deployment and correct repositioning before com-
lete dropping into place of the devices.
Early mortality is the most important criterion in apprais-
ng the results of thoracic aortic aneurysm treatment and in
omparing endovascular repair with conventional open sur-
ery. According to the literature, the 30-day mortality rates
ange between 0% and 15%.4,8,18,19,21,22,24-27 We report 
0-day mortality rate of 6.6%. Two patients died of severe
neumonopathy (keep in mind that chronic pulmonary dis-
ase was the main comorbidity), and 1 patient presented
ith an aortic-related 30-day death.
Paraplegia is one of the most feared complications after
epair of thoracic aneurysms. Although the endovascular
epair of thoracic aortic aneurysms shows a promising re-
uction in operative morbidity compared with open sur-
ery, the risk of spinal cord ischemia still exists. Accord-
ng to the literature, paraplegia occurs in 0% to 6.5% of
ases.4,10,18,21,25,27-29 Two (4.4%) of our patients present
ith paraplegia, one immediately. The other patient pre-
ented with secondary paraplegia after delayed hemody-
amic collapse. Despite appropriate medical treatment, in-
luding cerebrospinal fluid drainage, these patients did not
ecover from their deficit. Because of a limited number of
vents, we were unable to identify any risk factors for
araplegia.
As reported by other authors,4,10,18,21,25,27-29 the main
ostoperative complication of endovascular repair of aneu-
ysms of the descending thoracic aorta was cerebrovascular
ccident (13.3%). Because the encephalic injuries were dif-
usely positioned, the occurrence of a cerebrovascular acci-
ent can easily be explained by the manipulation of wires
nd catheters in an atherosclerotic aortic arch. We try to
inimize the risk of embolic stroke by limiting the manip-
lation within the aortic arch, particularly when severe
therosclerotic aortic arches are identified: we avoid han-
ling the guides as much as possible at the level of the aortic
alve and of the arch, a single guide wire is placed proxi-
ally to the aneurysm, we always maintain the rigid part of
he guide wire upstream of the dropping device to decrease
riction on the wall, and minimal progression of the unde-
loyed stent graft is performed across the arch.
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A
CDPrimary endoleak rates are similar to those encountered
n the infrarenal aorta (4.2% to 53%).23 Forty-two percent o
ur patients experienced primary endoleak, identified at the
nd of the procedure by means of angiography, transesoph-
geal echocardiography, or both. We observed type I
28.8%) and type III (11.1%) endoleaks and 1 type II
ndoleak related to an intercostal artery. Contrary to Green-
erg and associates,7 we do not conclude that the prese
f a primary endoleak should always be treated aggressively
ecause most of the primary type I endoleaks (7/13) spon-
aneously thrombosed during the first month. Of 13 primary
ype I endoleaks, 7 spontaneously healed during the first
onth, and 4 required reintervention with a good result.
ne patient with an aortoesophageal fistula died, and an-
ther with an increase of diameter died because of another
omplication preventing the performance of reintervention.
n fact, numbers of type I endoleaks are minor (mostly when
dentified on transesophageal echocardiography) and spon-
aneously heal, provided that the choice of the diameter of
he stent graft and its positioning are optimal. In these cases
e are content to model the prosthesis with a balloon to
chieve optimal proximal seal. In case of an evident error in
he diameter or in the positioning of the device, it is nec-
ssary to consider the use of a proximal long extension with
higher diameter (and not a cuff, which would not present
sufficient overlapping). If the endoleak persists, even
emotely, it would be necessary to perform reintervention.
wo patients experienced secondary endoleaks, 1 type I and
type III, during the first postoperative 30 days. Concerning
he secondary type I endoleak, the proximal neck was probably
oo short, whereas no technical failure was identified in the
econdary type III endoleak. Both of the secondary endoleaks
ere associated with aortic complications. No secondary en-
oleak was observed beyond postoperative day 30.
Despite a longer follow-up time than most of the refer-
nces in the literature, we did not observe any increased
ong-term complication rate. Six patients died, but only 2
eaths were potentially related to the treated aortic disease
2 unexplained sudden deaths).
imitations of Our Study and Current Prospects
ur work was prospective but monocentric and not random-
zed. Moreover, the number of complicating events and the
otal number of patients in the study made statistical anal-
sis challenging. In particular, we could not identify any
actor influencing the occurrence of paraplegia or endoleak.
he absence of late aortic complications is encouraging but
ight only be related to follow-up duration, which remains
hort. Longer follow-up remains necessary, and we cannot
xclude the occurrence of more delayed complications be-
ause of the evolution of the aortic morphology.30 Con-
rolled studies comparing conventional surgery and endo-
ascular repair in good surgical candidates and optimal
The Journal of Thoracicedical treatment versus endovascular repair in bad sur-
ical candidates would also be interesting. From a tech-
ical point of view, even if only very few consequences
f primary endoleak were observed, we tend to reduce
heir occurrence rate through a more rigorous selection of
he patients. This selection should not only be based on
hysiologic criteria but also on anatomic criteria. More-
ver, we tend to choose longer proximal and distal land-
ng zones, and we tend to perform more and more hybrid
rocedures associating extra-anatomic bypasses and en-
ovascular repair.
onclusions
ctually, short-term morbidity and mortality rates from
ndovascular treatment compare favorably with those from
urgical intervention, and stent graft placement is proving to
e a safe, minimally invasive, and effective treatment for
therosclerotic aneurysm of the descending thoracic aorta.
owever, the incidence of early and late complications
ighlights current challenges and underlines the necessity of
lose follow-up. Taking into account the gravity of the
atural evolution without medical treatment and the seri-
us and invasive nature of surgical treatment, endovas-
ular repair of aneurysms of the descending thoracic
orta seems to have a central place among selected pa-
ients at high surgical risk. Nevertheless, equivalence or
uperiority of endovascular repair compared with con-
entional open surgical treatment for patients at low
urgical risk has not been proved yet. The potential
ong-term risks of prosthetic degradation, migration, or
urgical conversion remain unknown, as do their effects
n survival. Further studies are still required to determine
he most relevant indications and the long-term efficacy
nd durability of this innovative technique.
We acknowledge the kind help of Mrs Barbara Hollington in
he preparation of the revised version of this manuscript.
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